drugset / Trial / NCT00935662

A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses

NCT00935662 ↗

Phase 1 Completed 119 enrolled AstraZeneca
RandomizedSingle-groupSingle-blindBasic science

Summary

The primary objective for this study is to assess the safety and tolerability of AZD8329 when given as a single dose in increasing dose strength, and also to identify the highest tolerated dose for future studies.

Timeline

Start
2009-07
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8329 Unknown — Oral

Indications

No indication recorded.